The U.S. pot sector could see an influx of medical research funding from healthcare investors amid renewed interest from pharmaceutical firms.
The U.S. pot sector could see an influx of medical research funding from healthcare investors amid renewed interest from pharmaceutical firms, should a proposal to reclassify cannabis as a lower-risk substance be approved, industry experts said.
